How should insurers assess the impact of new medicines and technologies?

This paper focuses on studying prevalent methodologies and best practices in assessing the impact of new technology and claims costs and medical inflation from the perspective of medical insurers and is primarily aimed at non-US insurers. It highlights differences in practices in different insurers and tries to close the gap between existing best practice, to allow a more consistent approach to assessment and measurement.